# US 2021/0079073 A1 · Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079073 A1
- Document ID: US20210079073A1
- Status: Published application
- Kind: A1
- Application number: 16/837,356
- Filed: 2020-04-01
- Published: 2021-03-18
- Earliest claimed: 2013-03-15
- Assignees: Novartis AG; The Trustees of the University of Pennsylvania
- Applicants: Novartis AG; The Trustees of the University of Pennsylvania
- Inventors: Michael C. Milone; Enxiu Wang
- Web page: https://patentgrep.com/patent/US20210079073A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/30: characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K 40/31: Chimeric antigen receptors [CAR]
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- A61K 2239/22: Intracellular domain
- A61K 2239/28: Expressing multiple CARs, TCRs or antigens
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/70: containing domain for protein-protein interaction
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).

## Claims

### Claim at position 1

-13. (canceled)

### Claim 14

A purified, or non-naturally occurring, inhibitory killer cell immunoglobulin-like receptor chimeric antigen receptor (inhKIR-CAR) comprising:
an extra-cellular antigen binding domain from an antibody molecule or a non-antibody scaffold;
a transmembrane domain, wherein the transmembrane domain is a inhKIR transmembrane domain or a transmembrane domain from an inhibitory receptor other than a KIR, and
a cytoplasmic domain,

### Claim at position 3

-21. (canceled)

### Claim 22 (depends on 14)

The inhKIR-CAR of claim 14, comprising a KIR-cytoplasmic domain.

### Claim 23

(canceled)

### Claim 24 (depends on 14)

The inhKIR-CAR of claim 14, wherein said antigen binding domain from an antibody molecule comprises an scFv.

### Claim 25 (depends on 14)

The inhKIR-CAR of claim 14, wherein said antigen binding domain from an antibody molecule comprises a single heavy chain variable domain (VH) domain.

### Claim 26 (depends on 14)

The inhKIR-CAR of claim 14, wherein said antigen binding domain comprises a nanobody.

### Claim 27

(canceled)

### Claim 28 (depends on 14)

The inhKIR-CAR of claim 14, comprising an extracellular hinge domain.

### Claim 29 (depends on 14)

The inhKIR-CAR of claim 14, comprising an extracellular hinge domain that:
(i) is other than a KIR hinge domain;
(ii) is derived from a natural molecule;
(iii) comprises a non-naturally occurring polypeptide sequence;
(iv) is from human CD8-alpha;
(v) is of less than 50, 20, or 10 amino acids in length, or
(vi) has fewer amino acids than a KIR2DS2 hinge domain.

### Claim at position 12

-52. (canceled)

### Claim 53 (depends on 14)

The inhKIR-CAR of claim 14, wherein said inhKIR-CAR comprises an inhKIR cytoplasmic domain.

### Claim 54 (depends on 14)

The inhKIR-CAR of claim 14, wherein said transmembrane domain from an inhibitor receptor other than a KIR comprises a transmembrane domain from PD-1, CTLA4 or ITIM-containing receptors from ILT (CD85), Siglec, LMIR (CD300) and/or SLAM gene families of receptors.

### Claim 55 (depends on 14)

The inhKIR-CAR of claim 14, wherein said cytoplasmic domain comprises a cytoplasmic domain from an inhibitory receptor other than a KIR.

### Claim 56 (depends on 55)

The inhKIR-CAR of claim 55, wherein said cytoplasmic domain from an inhibitory receptor other than a KIR comprises a cytoplasmic domain from PD-1, CTLA4 or ITIM-containing receptors from ILT (CD85), Siglec, LMIR (CD300) and/or SLAM gene families of receptors.

### Claim 57 (depends on 14)

The inhKIR-CAR of claim 14, wherein said cytoplasmic domain comprises an immunoreceptor tyrosine-based inhibitory motif (ITIM).

### Claim 58 (depends on 14)

The inhKIR-CAR of claim 14, comprising a KIR D domain.

### Claim 59 (depends on 14)

The inhKIR-CAR of claim 14, comprising a KIR D0 domain, a KIR D1 domain, or a KIR D2 domain.

### Claim at position 20

-61. (canceled)

### Claim 62 (depends on 14)

The inhKIR-CAR of claim 14, wherein said inhKIR-CAR does not comprise a KIR D domain.

### Claim 63 (depends on 14)

The inhKIR-CAR of claim 14, wherein said antigen binding domain binds an antigen not present on a target cell, e.g., a cancer cell, or wherein said antigen binding domain binds an antigen that is more highly expressed on a non-cancer cell than a cancer cell of the same type as the cancer cell.

### Claim 64

(canceled)

### Claim 65 (depends on 14)

The inhKIR-CAR of claim 14, wherein said antigen binding domain binds desmoglein1/3 (DSG1/3), an ephrin receptor, or a claudin.

### Claim at position 25

-253. (canceled)

### Claim 254 (depends on 14)

The inhKIR-CAR of claim 14, wherein said antigen binding domain from an antibody molecule comprises an immunoglobulin single domain antibody (sdAb).

### Claim 255 (depends on 14)

The inhKIR-CAR of claim 14, wherein said antigen binding domain from an antibody molecule comprises a single light chain variable domain (VL).

### Claim 256 (depends on 14)

The inhKIR-CAR of claim 14, comprising a KIR2DL or KIR3DL cytoplasmic domain.
